Bulletin
Investor Alert

Eli Lilly & Co.

NYS: LLY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Feb 25, 2021, 7:58 p.m.

LLY
/zigman2/quotes/200106384/composite

$

203.00

Change

-0.82 -0.40%

Volume

Volume 254,286

Quotes are delayed by 20 min

/zigman2/quotes/200106384/composite

Today's close

$ 204.52

$ 203.82

Change

-0.70 -0.34%

Day low

Day high

$201.75

$205.55

Open

52 week low

52 week high

$117.06

$218.00

Open

Company Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Valuation

P/E Current

30.13

P/E Ratio (with extraordinary items)

30.13

P/E Ratio (without extraordinary items)

24.87

Price to Sales Ratio

6.28

Price to Book Ratio

28.63

Price to Cash Flow Ratio

23.70

Enterprise Value to EBITDA

20.45

Enterprise Value to Sales

6.81

Total Debt to Enterprise Value

0.10

Efficiency

Revenue/Employee

701,137.00

Income Per Employee

176,963.00

Receivables Turnover

3.94

Total Asset Turnover

0.57

Liquidity

Current Ratio

1.40

Quick Ratio

1.08

Cash Ratio

0.29

Profitability

Gross Margin

77.66

Operating Margin

27.91

Pretax Margin

29.46

Net Margin

25.24

Return on Assets

14.42

Return on Equity

150.18

Return on Total Capital

33.38

Return on Invested Capital

31.65

Capital Structure

Total Debt to Total Equity

294.16

Total Debt to Total Capital

74.63

Total Debt to Total Assets

35.59

Long-Term Debt to Equity

294.01

Long-Term Debt to Total Capital

74.59

Officers and Executives

Name Age Officer Since Title
Mr. David A. Ricks 51 1996 President-Bio Medicines & Senior Vice President
Ms. Anat Ashkenazi 47 2013 Chief Financial Officer-Lilly Oncology
Dr. Timothy J. Garnett - 1998 Chief Medical Officer & VP-Global Medical
Dr. Aarti S. Shah 55 1994 Global Brand Leader-Autoimmune Division
Dr. Daniel M. Skovronsky 46 2018 Senior VP-Science & Technology Business

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/16/2021 Jackson Peter Tai
Director
10   Award at $205.76 per share. 2,057
02/16/2021 Ralph Alvarez
Director
53   Award at $207.76 per share. 11,011
02/08/2021 David A. Ricks
President & CEO; Director
130,343   Award at $205.77 per share. 26,820,679
02/08/2021 Stephen F. Fry
SVP, HR & Diversity
26,133   Award at $205.77 per share. 5,377,387
02/08/2021 Daniel M. Skovronsky
SVP, CSO, and Pres. LRL
18,521   Award at $205.77 per share. 3,811,066
02/08/2021 Myles Oneill
SVP & Pres., Mfg. Operations
21,052   Award at $205.77 per share. 4,331,870
02/08/2021 Joshua L. Smiley
25,409   Award at $205.77 per share. 5,228,409
02/08/2021 Alfonso G. Zulueta
SVP & President, Lilly Int l
29,037   Award at $205.77 per share. 5,974,943
02/08/2021 Melissa Stapleton Barnes
Chief Eth/Cmpl Ofcr & SVP, ERM
9,594   Award at $205.77 per share. 1,974,157
02/08/2021 Anne E. White
SVP & Pres-Lilly Oncology
4,718   Award at $205.77 per share. 970,822
02/08/2021 Aarti S. Shah
SVP & CIDO
11,033   Award at $205.77 per share. 2,270,260
02/08/2021 Patrik Jonsson
SVP & President Lilly USA
5,595   Award at $205.77 per share. 1,151,283
02/08/2021 Johna L. Norton
Senior VP, Global Quality
6,040   Award at $205.77 per share. 1,242,850
02/08/2021 Mike Mason
Sr. VP & Pres., Lilly Diabetes
6,350   Award at $205.77 per share. 1,306,639
02/08/2021 Leigh Ann Pusey
SVP, Corp. Affairs & Comm.
10,791   Award at $205.77 per share. 2,220,464
02/08/2021 Anat Ashkenazi
SVP & CFO
7,975   Award at $205.77 per share. 1,641,015
02/08/2021 Donald A. Zakrowski
Chief Accounting Officer
4,247   Award at $205.77 per share. 873,905
02/08/2021 Ilya Yuffa
SVP and Pres, Lilly Bio-Meds
3,536   Award at $205.77 per share. 727,602
02/01/2021 David A. Ricks
President & CEO; Director
33,738   Derivative/Non-derivative trans. at $207.97 per share. 7,016,491
02/01/2021 Stephen F. Fry
SVP, HR & Diversity
6,746   Derivative/Non-derivative trans. at $207.97 per share. 1,402,965
02/01/2021 Myles Oneill
SVP & Pres., Mfg. Operations
5,438   Derivative/Non-derivative trans. at $207.97 per share. 1,130,940
02/01/2021 Joshua L. Smiley
8,452   Derivative/Non-derivative trans. at $207.97 per share. 1,757,762
02/01/2021 Alfonso G. Zulueta
SVP & President, Lilly Int l
7,490   Derivative/Non-derivative trans. at $207.97 per share. 1,557,695
02/01/2021 Melissa Stapleton Barnes
Chief Eth/Cmpl Ofcr & SVP, ERM
2,403   Derivative/Non-derivative trans. at $207.97 per share. 499,751
02/01/2021 Aarti S. Shah
SVP & CIDO
2,780   Derivative/Non-derivative trans. at $207.97 per share. 578,156
02/01/2021 Johna L. Norton
Senior VP, Global Quality
1,529   Derivative/Non-derivative trans. at $207.97 per share. 317,986
02/01/2021 Leigh Ann Pusey
SVP, Corp. Affairs & Comm.
2,854   Derivative/Non-derivative trans. at $207.97 per share. 593,546
02/01/2021 David A. Ricks
President & CEO; Director
75,387   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Stephen F. Fry
SVP, HR & Diversity
15,078   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Myles Oneill
SVP & Pres., Mfg. Operations
12,146   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Joshua L. Smiley
19,266   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Alfonso G. Zulueta
SVP & President, Lilly Int l
16,754   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Melissa Stapleton Barnes
Chief Eth/Cmpl Ofcr & SVP, ERM
5,445   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Aarti S. Shah
SVP & CIDO
6,282   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Johna L. Norton
Senior VP, Global Quality
3,435   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2021 Leigh Ann Pusey
SVP, Corp. Affairs & Comm.
6,282   Derivative/Non-derivative trans. at $0 per share. 0
01/19/2021 Jackson Peter Tai
Director
10   Award at $198.48 per share. 1,984
01/19/2021 Ralph Alvarez
Director
55   Award at $198.48 per share. 10,916
01/15/2021 Lilly Endowment, Inc.
148,766   Disposition at $191.14 per share. 28,435,133
01/15/2021 Lilly Endowment, Inc.
41,298   Disposition at $190.49 per share. 7,866,856
01/15/2021 Lilly Endowment, Inc.
24,936   Disposition at $189.3 per share. 4,720,384
01/13/2021 Lilly Endowment, Inc.
9,722   Disposition at $187.12 per share. 1,819,180
01/13/2021 Lilly Endowment, Inc.
95,353   Disposition at $186.47 per share. 17,780,473
01/13/2021 Lilly Endowment, Inc.
104,925   Disposition at $185.4 per share. 19,453,095
01/11/2021 Lilly Endowment, Inc.
300   Disposition at $187.46 per share. 56,238
01/11/2021 Lilly Endowment, Inc.
48,871   Disposition at $187 per share. 9,138,877
01/11/2021 Lilly Endowment, Inc.
42,301   Disposition at $185.63 per share. 7,852,334
01/11/2021 Lilly Endowment, Inc.
128,528   Disposition at $184.87 per share. 23,760,971
12/21/2020 Jackson Peter Tai
Director
12   Award at $168.78 per share. 2,025
11/16/2020 Kathi P. Seifert
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Jon Erik Fyrwald
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Jackson Peter Tai
Director
1,259   Award at $140.59 per share. 177,002
11/16/2020 Ralph Alvarez
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Michael L. Eskew
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Katherine Baicker
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 William G. Kaelin
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Marschall S. Runge
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Juan Ricardo Luciano
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Jamere Jackson
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Carolyn R. Bertozzi
Director
1,245   Award at $140.59 per share. 175,034
11/16/2020 Karen Walker
Director
1,245   Award at $140.59 per share. 175,034
10/19/2020 Jackson Peter Tai
Director
14   Award at $142.8 per share. 1,999
/news/latest/company/us/lly

MarketWatch News on LLY

  1. Riell shares jump 31% premarket

    6:38 a.m. Feb. 18, 2021

    - Ciara Linnane

  2. Eli Lilly to pay Rigel $125 mln upfront, up to $835 mln in future milestone payments

    6:37 a.m. Feb. 18, 2021

    - Ciara Linnane

  3. Eli Lilly and Rigel to codevelop Rigel's treatment for immunological and neurodegenerative diseases

    6:37 a.m. Feb. 18, 2021

    - Ciara Linnane

  4. 5 Affordable Biopharma Stocks With Growth Potential

    12:06 p.m. Feb. 17, 2021

    - Josh Nathan-Kazis

  5. Vir and GSK Will Collaborate on Flu Therapy

    9:30 a.m. Feb. 17, 2021

    - Josh Nathan-Kazis

  6. Vir and GSK Will Collaborate on Flu Therapy

    9:29 a.m. Feb. 17, 2021

    - Josh Nathan-Kazis

  7. Eli Lilly Executives Enthusiastic About Alzheimer's Drug, Analyst Says

    10:00 a.m. Feb. 12, 2021

    - Josh Nathan-Kazis

  8. Eli Lilly says CFO Smiley had 'inappropriate' personal communications with certain employees

    7:04 a.m. Feb. 9, 2021

    - Ciara Linnane

  9. Eli Lilly names Anat Ashkenazi CFO replacing Josh Smiley who is resigning

    7:03 a.m. Feb. 9, 2021

    - Ciara Linnane

  10. Biogen’s Alzheimer’s Drug Faces a Big Test

    1:44 p.m. Feb. 7, 2021

    - Josh Nathan-Kazis

  11. The Coming Alzheimer’s Crisis

    1:27 p.m. Feb. 7, 2021

    - Reshma Kapadia

  12. Loading more headlines...
/news/nonmarketwatch/company/us/lly

Other News on LLY

  1. Merck Makes Another Move to Beef Up Drug Business

    3:51 p.m. Today

    - GuruFocus.com

  2. Lilly's migraine med approved in Canada for episodic cluster headache

    2:50 p.m. Today

    - Seeking Alpha

  3. United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

    7:54 a.m. Today

    - Zacks.com

  4. RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today

    8:17 a.m. Feb. 24, 2021

    - InvestorPlace.com

  5. Big Pharma Short Percentage Is Below Overall Market

    4:18 p.m. Feb. 23, 2021

    - GuruFocus.com

  6. 10-K: HALOZYME THERAPEUTICS, INC.

    4:15 p.m. Feb. 23, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  7. Why Piotroski's F-Score No Longer Works

    10:10 a.m. Feb. 20, 2021

    - Seeking Alpha

  8. Avidity Biosciences shares soar 18% in afternoon trading

    3:30 p.m. Feb. 19, 2021

    - Seeking Alpha

  9. RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today

    2:48 p.m. Feb. 18, 2021

    - InvestorPlace.com

  10. Loading more headlines...

At a Glance

Eli Lilly & Co.

Lilly Corporate Center

Indianapolis, Indiana 46285

Phone

1 3172762000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$24.54B

Net Income

$6.19B

2020 Sales Growth

9.9%

Employees

35,000

/news/pressrelease/company/us/lly

Press Releases on LLY

  1. Global cancer immunotherapy market valuation to cross USD 1 billion by 2026

    2:08 p.m. Today

    - Market Insight Reports

  2. Endocrinology Drugs Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast to 2025

    1:56 p.m. Today

    - Market Insight Reports

  3. Alzheimer’s Disease Therapeutics and Diagnostics: Global Markets

    12:28 p.m. Today

    - Heraldkeepers

  4. Conventional and Alternative Pain Treatment Markets

    12:07 p.m. Today

    - Heraldkeepers

  5. Hepatocellular carcinoma (HCC)- Market Insights, Epidemiology and Market Forecast-2028

    11:25 a.m. Today

    - Heraldkeepers

  6. Pharmaceuticals for Women’s Health: Global Markets

    11:25 a.m. Today

    - Heraldkeepers

  7. Anti-Infective Drugs Global Market Report 2021: COVID 19 Implications and Growth to 2030

    11:06 a.m. Today

    - GlobeNewswire

  8. Are These Top Health Care Stocks Worth Watching Ahead Of March?

    9:14 a.m. Today

    - StockMarket.com

  9. Pharmaceutical Pricing and Reimbursement: Global Markets

    8:59 a.m. Today

    - Heraldkeepers

  10. Health Technology Assessment in Pharma: A Review of Major Decisions

    8:25 a.m. Today

    - Heraldkeepers

  11. Latest Development, Product Innovations and Treatments for Diabetes

    7:42 a.m. Today

    - Heraldkeepers

  12. Stress Management Industry: Global Trends

    7:42 a.m. Today

    - Heraldkeepers

  13. Erectile Dysfunction Drugs Market Size, Share to reach around $ 2.63 Bn by 2025 - Industry News

    5:35 a.m. Today

    - Market Insight Reports

  14. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.